Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807352 | 1.00 | CYP2D6 (0.48) | CYP2D6SRCDPP4LMNAMAPK1 | |
| SCHEMBL14935796 | 1.00 | CYP2D6 (0.48) | CYP2D6SRCDPP4LMNAMAPK1 | |
| Methane SCHEMBL4340079 | 0.98 | CYP2D6 (0.46) | CYP2D6SRCDPP4LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL8695663 | 0.98 | CYP2D6 (0.46) | CYP2D6SRCDPP4LMNAMAPK1 | |
| SCHEMBL995792 | 0.83 | DPP4 (0.44) | CYP2D6SRCDPP4LMNACTSD | |
| SCHEMBL28513 | 0.83 | TDP1 (0.44) | CYP2D6SRCLMNASLC1A2SLC1A3 | |
| SCHEMBL29779 | 0.83 | TDP1 (0.44) | CYP2D6SRCLMNASLC1A2SLC1A3 | |
| SCHEMBL27675527 | 0.82 | MMP8 (0.42) | CYP2D6SLC1A2SLC1A3SLC1A1TSHR | |
| Hydrochloric Acid SCHEMBL28838130 | 0.82 | TDP1 (0.43) | CYP2D6SRCLMNASLC1A2SLC1A3 | |
| SCHEMBL6945331 | 0.79 | KMT2A (0.56) | CYP2D6DPP4LMNAMAPK1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114457049-B | Pyrrolysiyl-tRNA synthetase mutant and application thereof | 浙江大学杭州国际科创中心 | 2024-09-24 | — | — | CN | claimed |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | US | claimed |
| CN-116390742-A | Cyclic chemokine-9 derivatives | 拜耳公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4196143-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2023-06-21 | — | — | EP | claimed |
| CN-114457049-A | Pyrrolysinyl-tRNA synthetase mutant and application thereof | 浙江大学杭州国际科创中心 | 2022-05-10 | — | — | CN | claimed |
| WO-2022034057-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-17 | — | — | WO | claimed |
| WO-2019179985-A1 | INHIBITORS OF MINT AND USES THEREOF | UNIVERSITY OF COPENHAGEN (DK) | 2019-09-26 | — | — | WO | claimed |
| US-20160022636-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | claimed |
| EP-2968240-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | claimed |
| US-20140336216-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | claimed |
| WO-2014152917-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | claimed |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | TRANSFERT PLUS LP (CA) | 2026-03-26 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-12492422-B2 | Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment | Sunbird Bio, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-1046634-A1 | PROCESSES FOR PRODUCING BETA-HALOGENO-ALPHA-AMINO-CARBOXYLIC ACIDS AND PHENYLCYSTEINE DERIVATIVES AND INTERMEDIATES THEREOF | KANEKA CORPORATION (JP) | 2000-10-25 | — | — | EP | disclosed |
| EP-0206460-B1 | L-PHENYLALANINE DEHYDROGENASE AND USE THEREOF | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1993-08-11 | — | — | EP | disclosed |
| EP-0513872-A1 | L-phenylalanine dehydrogenase and use thereof | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-11-19 | — | — | EP | disclosed |
| US-4849345-A | L-phenylalanine dehydrogenase and use thereof | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1989-07-18 | — | — | US | disclosed |
| EP-0206460-A2 | L-phenylalanine dehydrogenase and use thereof | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | CYP2D6 4444/4885SRC 3066/4885DPP4 109/4885 |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | CMKLR1, CMKLR2, CCL2 | CYP2D6 4545/4885SRC 2775/4885DPP4 671/4885 |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | VSIG8, MICA, CD74 | CYP2D6 4548/4885SRC 3967/4885DPP4 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.